Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Analysts remain bullish on Taysha Gene Therapies: Fourteen analysts have issued an average “Buy” recommendation, with a consensus 12-month price target of $12.77.
• TSHA shares opened at $5.02, compared with a 52-week range of $2.71 to $7.30. The company reported a quarterly loss of $0.13 per share, missing the $0.11-per-share consensus estimate.
• Institutional investors own 77.7% of the stock, while several hedge funds increased their positions during the second quarter. An insider separately sold 200,000 shares for approximately $1.25 million under a pre-arranged trading plan.

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received an average recommendation of "Buy" from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $12.7692.

TSHA has been the subject of a number of research reports. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Citizens Jmp reiterated a "market outperform" rating and set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. BMO Capital Markets increased their price objective on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 23rd. Needham & Company LLC restated a "buy" rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $5.02 on Friday. The firm has a market cap of $1.64 billion, a PE ratio of -11.95 and a beta of 1.19. Taysha Gene Therapies has a 52-week low of $2.71 and a 52-week high of $7.30. The business's 50 day moving average price is $5.93 and its two-hundred day moving average price is $5.65. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities analysts anticipate that Taysha Gene Therapies will post -0.52 EPS for the current year.

Insider Buying and Selling

In other news, insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the sale, the insider owned 936,410 shares in the company, valued at $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company's stock.

Institutional Trading of Taysha Gene Therapies

Hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP acquired a new position in Taysha Gene Therapies during the second quarter worth $709,000. Squarepoint Ops LLC raised its holdings in shares of Taysha Gene Therapies by 38.8% in the 2nd quarter. Squarepoint Ops LLC now owns 569,269 shares of the company's stock worth $3,877,000 after acquiring an additional 158,987 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Taysha Gene Therapies by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 39,633 shares of the company's stock worth $270,000 after acquiring an additional 2,014 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of Taysha Gene Therapies by 742.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,153,437 shares of the company's stock worth $7,855,000 after acquiring an additional 1,016,504 shares during the last quarter. Finally, Seven Fleet Capital Management LP lifted its position in Taysha Gene Therapies by 140.4% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,504,400 shares of the company's stock valued at $9,940,000 after acquiring an additional 878,692 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.